Diffuse Large B-cell Lymphoma
Conditions
Brief summary
To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.
Detailed description
This study retrospectively collected the data of patients previously treated with Tafa and divided them into two coords according to different protocols received. Cohort 1 was Tafa combined treatment group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitor, Tafa combined with Lenalidomide plus chemotherapy (including ADC). Cohort 2 was treated with sequential CAR T or graft after Tafa combination therapy.
Interventions
DRUGTafasitamab Injection
The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
Sponsors
Zhao Weili
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients with pathological diagnosis of DLBCL, including but not limited to non-specific DLBCL (NOS-DLBCL); Large B-cell lymphoma (THRLBCL) rich in T cells/histiocytes; EBV positive DLBCL (EBV-positive DLBCL); According to the revised REAL/WHO classification, it was grade 3b follicular lymphoma, including DLBCL component, followed by DLBCL recurrence. In addition, patients with low-grade lymphomas such as follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia have histological evidence of transformation to DLBCL and subsequent recurrence * Patients who, as determined by the treating physician, would benefit from Tafa treatment
Exclusion criteria
* Known allergy or metabolic disorder to any drug in the regimen * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period * Have a history of uncontrolled medical disease (including uncontrolled diabetes, severe heart, lung, liver, renal insufficiency), blood, endocrine system, and other malignancies * Severe mental illness * Patients deemed unsuitable for inclusion by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective remission rate | at the end of Cycle 2 (each cycle is 28 days) | Defined as the proportion of patients with CR and PR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 1year after induction therapy | The time between the start of treatment and when the tumor progresses or the patient dies |
Countries
China
Outcome results
None listed